Breaking News

Chugai Pharma Appoints CMO

April 25, 2014

Gianella-Borradori brings 20 years of R&D experience

Athos Gianella-Borradori, M.D. has been appointed chief medical officer of Chugai Pharma USA, LLC, a subsidiary of Chugai Pharmaceutical Co. of Tokyo, Japan, and member of the Roche Group.
 
Dr. Gianella-Borradori is pediatric hematologist-oncologist and executive with more than 20 years of international R&D experience focusing on translational research and clinical development of novel therapeutics. He has held senior R&D positions at Novartis, Crucell, Bavarian Nordic, Cyclacel, Merck Serono, and Clavis Pharma. 
 
Dr. Gianella-Borradori is responsible for all clinical activity in the U.S. and will provide leadership for scientific and translational committees in Japan at the parent company. He represents the company in relationships with the FDA, academia, clinical investigators and patient communities, and is responsible for increasing the awareness of Chugai to facilitate its expanding clinical activity in the U.S.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016